💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Amarin Corporation PLC (AMRN)
« Back to company indexAMRN Chatter Timeline
Stock Ticker for AMRN
Most Active Tweeters for AMRN
| User | Tweets |
|---|---|
| @yudi_lks | 9 |
| @MatthewTNatale | 6 |
| @chiragontwtr | 6 |
| @hedgiesinvest | 4 |
| @ra_fun | 4 |
Recent Tweets for AMRN
 |
@StockPyf Take a look at this Watchlist: $AMRN $ARTL #scnDollHiVol DateTime: 2020-10-19 15:48 ET October 19th 2020, 3:10pm |
 |
@GivemeOcean @jimcramer You made a great call on $amrn too at $21 to buy October 19th 2020, 1:10pm |
 |
@hedgiesinvest $AMRN If Shareholders can raise $10k in a few days, then file an Amicus we can certainly pursue a derivative suit.… https://t.co/1NriOKbqP1 October 19th 2020, 12:10pm |
 |
@YuZhu4 RT @TerraPharma1: ? Fierce Biotech: The Top 10 Takeover Targets in Biopharma Coming in at Number 2 is Amarin $AMRN #vascepa https://t.c… October 19th 2020, 10:10am |
 |
@otcdynamics $AMRN Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 https://t.co/tOoM2pKrvg October 19th 2020, 7:10am |
 |
@nubostongeorge $AMRN - Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 https://t.co/NFy9ztdlJ1 October 19th 2020, 7:10am |
 |
@VisualStockRSRC $AMRN - Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 https://t.co/WNeM0XTUbI October 19th 2020, 7:10am |
 |
@FlashAlert_me $AMRN [15s. delayed]: Issued Press Release on October 19, 07:00:00: Amarin to Report Third Quarter 2020 Results and… https://t.co/VAkNZGuZXQ October 19th 2020, 7:10am |
 |
@stock_titan $AMRN Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 https://t.co/9Q4dKxpgVu October 19th 2020, 7:10am |
 |
@TerraPharma1 ? Fierce Biotech: The Top 10 Takeover Targets in Biopharma Coming in at Number 2 is Amarin $AMRN #vascepa… https://t.co/L0MVo3BgrG October 19th 2020, 6:10am |
 |
@FaZe_VascepA $AMRN 0.7 KD bot jizzes on 5 guys for miracle clutch WOW #CallofDutyModernWarfare #XboxShare #FaZe5 @barnidgefan https://t.co/bnGSwnYGRk October 18th 2020, 7:10pm |
|
@FaZe_VascepA https://t.co/NmExQW3HDU #Warzone Buy Back Duos — absolute heaters #Elite ? #XboxShare $AMRN $ACB 20bombincoming October 17th 2020, 1:10pm |
 |
@ConvictionCap_ $amrn interesting to see amicus pop up last night, although most likely meaningless. Expecting to see en banc denie… https://t.co/dTwWhtQoL5 October 17th 2020, 10:10am |
|
@curtis_withers RT @AJDWIEN: Analysis of Amarin's Vascepa to drive increased market share, says Piper Sandler Price Target: 21$ $amrn #amarin #vascepa htt… October 16th 2020, 8:10pm |
|
@Jb_118 @tuduylinh @semodough Agree. $AMRN got notified of their AdCom (and delayed PDUFA) 40-45 days prior to their first… https://t.co/DAVRLzZQ0a October 16th 2020, 5:10pm |
|
@YuZhu4 RT @ra_fun: "Piper Sandler analyst Yasmeen Rahimi keeps an Overweight rating and $21 price target on Amarin..." $AMRN https://t.co/AWw22sr… October 16th 2020, 4:10pm |
|
@hedgiesinvest $AMRN What is management doing to promote shareholder value? How about talking to the FDA about adding Evaporate to… https://t.co/onPRPhGuM8 October 16th 2020, 2:10pm |
 |
@mchaudhry82 $AMRN Amarin call volume above normal and directionally bullish https://t.co/Tqj5ayg2Sw October 16th 2020, 1:10pm |
|
@bocadmk $amrn 50 day has moved down to 5.41. matter of hours... October 16th 2020, 12:10pm |
 |
@OG_Cdquality RT @kylewdennis: Love it on $AMRN! https://t.co/IBdM0vKNao October 16th 2020, 12:10pm |
 |
@gcassidy718 $AMRN "Everything is impossible until someone does it" 2.02 % change recently https://t.co/ptfWB4ucJa October 16th 2020, 12:10pm |
 |
@Orangeman1992 @MedResCol How many shares at $1.34. I have no skin in the game. But I followed you on $AMRN October 16th 2020, 11:10am |
 |
@AJDWIEN Analysis of Amarin's Vascepa to drive increased market share, says Piper Sandler Price Target: 21$ $amrn #amarin… https://t.co/rmzffNDyWz October 16th 2020, 10:10am |
 |
@jannik_reiners $AMRN Federal circuit judges consulting regarding en banc review. https://t.co/SJiiLNOXOi October 16th 2020, 10:10am |
 |
@yudi_lks RT @Pharmdca: Great drug Vascepa unfortunately company couldn’t convince and lost on the patent war $AMRN October 15th 2020, 7:10pm |
|
@yudi_lks RT @JorelLaraKalel: Amarin gains after Vascepa found to significantly reduce ischemic events in PCI patients $AMRN https://t.co/wDEPt35QNw… October 15th 2020, 7:10pm |
|
@yudi_lks RT @AmpBioResearch: $AMRN - VASCEPA® Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interventio… October 15th 2020, 7:10pm |
|
@yudi_lks RT @MarcJacksonLA: $AMRN Vascepa Found To Significantly Reduce Ischemic Events In Patients With Prior Percutaneous Coronary Intervention (P… October 15th 2020, 7:10pm |
|
@yudi_lks RT @HealthcareBeat: Amarin gains after Vascepa found to significantly reduce ischemic events in PCI patients $AMRN https://t.co/eGqQ8SXTWI October 15th 2020, 7:10pm |
 |
@HealthcareBeat Amarin gains after Vascepa found to significantly reduce ischemic events in PCI patients $AMRN https://t.co/eGqQ8SXTWI October 15th 2020, 7:10pm |
 |
@MarcJacksonLA $AMRN Vascepa Found To Significantly Reduce Ischemic Events In Patients With Prior Percutaneous Coronary Interventi… https://t.co/pnNdbfo3N0 October 15th 2020, 7:10pm |
 |
@AmpBioResearch $AMRN - VASCEPA® Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interve… https://t.co/rRI90pAhIL October 15th 2020, 5:10pm |
|
@bocadmk $amrn oh boy... October 15th 2020, 5:10pm |
 |
@justinburkhard1 RT @BioStocks: $AMRN VASCEPA Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI)… October 15th 2020, 4:10pm |
 |
@darylmox RT @Pharmdca: Great drug Vascepa unfortunately company couldn’t convince and lost on the patent war $AMRN https://t.co/2LcvlSDhrA October 15th 2020, 4:10pm |
 |
@MarketCurrents $AMRN - Amarin gains after Vascepa found to significantly reduce ischemic events in PCI patients https://t.co/TnakQLIyhj October 15th 2020, 4:10pm |
 |
@ArmengolRivera Watching $AMRN and see if it curls on good news October 15th 2020, 4:10pm |
|
@TerraPharma1 $HLS.TO $AMRN https://t.co/tj3QaxlcxM October 15th 2020, 4:10pm |
 |
@quant_data Amarin Highlights Presentation Of REDUCE-IT Study Of VASCEPA Related Tickers: $AMRN October 15th 2020, 4:10pm |
 |
@Pharmdca Great drug Vascepa unfortunately company couldn’t convince and lost on the patent war $AMRN https://t.co/2LcvlSDhrA October 15th 2020, 4:10pm |
 |
@leopoldtrader73 $AMRN bot for long term hold here 5.25 October 15th 2020, 4:10pm |
 |
@PhDInvestor Here we go again. $AMRN https://t.co/KiRtDtmqA9 October 15th 2020, 4:10pm |
 |
@BioStocks $AMRN VASCEPA Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interventi… https://t.co/TmMW5XpCKu October 15th 2020, 4:10pm |
 |
@SwingTradeIdeas $AMRN is up 5.54% after hours on 268,589 volume. Now trading at $5.33. #AMRN #afterhoursscan October 15th 2020, 4:10pm |
|
@otcdynamics $AMRN VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous… https://t.co/XNHqEldoWh October 15th 2020, 4:10pm |
 |
@Junior21503501 Watching $AMRN Consistent and robust benefit news.. Keeping an eye on it October 15th 2020, 4:10pm |
 |
@biobuddha 2020: The rise and fall of $AMRN vs the fall and rise of $TRIL! What a year! October 15th 2020, 4:10pm |
|
@SwingTradeIdeas $AMRN is up 8.51% after hours on 195,823 volume. Now trading at $5.48. #AMRN #afterhoursscan October 15th 2020, 4:10pm |
 |
@sbwcws Amarin shares jump 9.3% after Vascepa data in patients with prior PCI $AMRN October 15th 2020, 4:10pm |
|
@nubostongeorge $AMRN - VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior https://t.co/CHhPm8kaXW October 15th 2020, 4:10pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2020. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
- ✓ Patent Expirations and Generic Entry
- ✓ 505(b)(2) & Biosimilars
- ✓ Insightful Articles and Case Studies
- ✓ Patent Litigation & Challenges
- ✓ Industry Trends
